No. 12/21.09.2018
To:
Bucharest Stock Exchange
Financial Supervisory Authority
Notification concerning the transactions made under the buy-back program, in compliance with FSA Regulation no. 5/2018 on issuers of financial instruments and market operations and the Commission Delegated Regulation 2016/1052
Issuer name: Ropharma SA
Headquarters: 55 Iuliu Maniu Street, 1st floor, Brasov
Sole registration number: 1962437, fiscal attribute RO
Trade Register Number: J8/2886/2007
LEI Code: 2138004ATSD4SVFAZ789
Share capital: 51.126.741,3 lei
Regulated market on which the issued shares are traded: BVB, Standard
ROPHARMA S.A. reports the following information regarding the buy-back transactions made in the period September 13 – 20, 2018:
Issuer name (Buyer) – ROPHARMA S.A.
Intermediary name – TRADEVILLE S.A.
Description of the acquired financial instruments – ordinary shares issued by Ropharma S.A. (RPH)
Type of transaction: Buy
Buy-back transactions details:
Buyback transactions for the period Sept 13-20, 2018 (detailed)
|
No.
|
Date
|
Time
|
Market
|
Symbol
|
Volume
|
Price
|
Value
|
1
|
13.09.2018
|
10:05:01
|
BVB - REGS
|
RPH
|
200
|
0.28
|
56
|
2
|
13.09.2018
|
10:05:45
|
BVB - REGS
|
RPH
|
1,620
|
0.28
|
453.6
|
3
|
14.09.2018
|
10:03:54
|
BVB - REGS
|
RPH
|
463
|
0.28
|
129.64
|
4
|
14.09.2018
|
10:43:06
|
BVB - REGS
|
RPH
|
1,387
|
0.28
|
388.36
|
5
|
17.09.2018
|
13:28:19
|
BVB - REGS
|
RPH
|
1,850
|
0.28
|
518
|
6
|
18.09.2018
|
16:19:19
|
BVB - REGS
|
RPH
|
1,880
|
0.28
|
526.4
|
7
|
20.09.2018
|
17:31:49
|
BVB - REGS
|
RPH
|
1,960
|
0.28
|
548.8
|
Buyback transactions for the period Sept 13-20, 2018 (Synthetic)
|
Date
|
Symbol
|
Operation type
|
Market
|
Currency
|
Volume
|
Price
|
Value
|
13.09.2018
|
RPH
|
Buy
|
BVB - REGS
|
RON
|
1,820
|
0.28
|
509.6
|
14.09.2018
|
RPH
|
Buy
|
BVB - REGS
|
RON
|
1,850
|
0.28
|
518
|
17.09.2018
|
RPH
|
Buy
|
BVB - REGS
|
RON
|
1,850
|
0.28
|
518
|
18.09.2018
|
RPH
|
Buy
|
BVB - REGS
|
RON
|
1,880
|
0.28
|
526.4
|
20.09.2018
|
RPH
|
Buy
|
BVB - REGS
|
RON
|
1,960
|
0.28
|
548.8
|
Dr. pharm. MIHAI MIRON
CEO